$AADI
Aadi Bioscience, Inc. Stock $aadi

$aadi Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000156459022010721 Filed on March 17, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$14.00M	$1.120M	$14.00M
YoY Change	0.0%	-92.32%
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$1.120M
YoY Change
Gross Profit Margin		100.0%
Selling, General & Admin	$9.718M	$18.51M	$2.405M
YoY Change	304.01%	111.26%	56.19%
% of Gross Profit		1652.77%
Research & Development	$7.227M	$19.67M	$3.230M
YoY Change	123.75%	31.06%	51.64%
% of Gross Profit		1756.25%
Depreciation & Amortization	$72.00K	$105.0K	$54.48K
YoY Change	32.16%	1066.67%	81.6%
% of Gross Profit		9.38%
Operating Expenses	$16.95M	$112.3M	$5.637M
YoY Change	200.62%	555.83%	21.03%
Operating Profit		-$111.2M
YoY Change		4263.16%
Interest Expense	-$45.00K	$665.0K	$2.360K
YoY Change	-2006.78%	-18.4%	-98.61%
% of Operating Profit
Other Income/Expense, Net		$1.129M	$916.6K
YoY Change		-44.7%	334.22%
Pretax Income	-$15.99M	-$110.1M	-$4.718M
YoY Change	238.94%	3067.09%	6.02%
Income Tax	$0.00	$2.000K
% Of Pretax Income
Net Earnings	-$15.99M	-$110.1M	-$4.718M
YoY Change	238.94%	3045.71%	6.02%
Net Earnings / Revenue	-114.21%	-9830.36%	-33.7%
Basic Earnings Per Share		-$12.41
Diluted Earnings Per Share	-$760.6K	-$12.34M	-$1.500M
COMMON SHARES
Basic Shares Outstanding		8.923M shares
Diluted Shares Outstanding		8.923M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$149.0M	$149.0M	$42.60M
YoY Change	249.7%	249.7%	10.66%
Cash & Equivalents	$149.0M	$149.0M	$4.455M
Short-Term Investments
Other Short-Term Assets	$2.283M	$2.283M	$1.604M
YoY Change	42.34%	7.99%	118.28%
Inventory	$0.00
Prepaid Expenses			$510.2K
Receivables	$0.00		$14.15M
Other Receivables
Total Short-Term Assets	$151.3M	$151.3M	$18.69M
YoY Change	709.59%	238.27%	-52.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.00K	$614.0K	$21.00K
YoY Change	171.43%	230.73%	-87.21%
Goodwill
YoY Change
Intangibles	$3.811M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.213M	$2.213M	$20.00K
YoY Change	10965.0%	10965.0%
Total Long-Term Assets	$6.638M	$6.638M	$140.0K
YoY Change	4641.43%	3127.97%	-61.78%
TOTAL ASSETS
Total Short-Term Assets	$151.3M	$151.3M	$18.69M
Total Long-Term Assets	$6.638M	$6.638M	$140.0K
Total Assets	$157.9M	$157.9M	$18.83M
YoY Change	738.83%	251.5%	-52.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.439M	$6.439M	$2.392M
YoY Change	169.19%	1131.07%	443.9%
Accrued Expenses	$8.703M	$8.576M	$4.099M
YoY Change	112.32%	538.2%	41.34%
Deferred Revenue
YoY Change
Short-Term Debt	$258.0K	$258.0K	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$15.27M	$15.27M	$30.06M
YoY Change	-49.19%	718.13%	801.56%
LONG-TERM LIABILITIES
Long-Term Debt	$5.757M	$5.757M	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$474.0K	$97.00K
YoY Change	-100.0%		-3.0%
Total Long-Term Liabilities	$0.00	$6.231M	$97.00K
YoY Change	-100.0%		-3.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.27M	$15.27M	$30.06M
Total Long-Term Liabilities	$0.00	$6.231M	$97.00K
Total Liabilities	$21.50M	$21.50M	$31.26M
YoY Change	-31.2%	1051.91%	818.93%
SHAREHOLDERS EQUITY
Retained Earnings	-$142.7M		-$32.60M
YoY Change	337.75%		-77.08%
Common Stock	$279.1M		$20.16M
YoY Change	1284.24%		-88.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$136.4M	$136.4M	-$12.43M
YoY Change
Total Liabilities & Shareholders Equity	$157.9M	$157.9M	$18.83M
YoY Change	738.83%	251.5%	-52.86%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$15.99M	-$110.1M	-$4.718M
YoY Change	238.94%	3045.71%	6.02%
Depreciation, Depletion And Amortization	$72.00K	$105.0K	$54.48K
YoY Change	32.16%	1066.67%	81.6%
Cash From Operating Activities	-$12.43M	-$22.42M	$4.041M
YoY Change	-407.54%	76.55%	-183.15%
INVESTING ACTIVITIES
Capital Expenditures	-$46.00K	$46.00K	-$19.03K
YoY Change	141.72%	141.79%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$25.20M
YoY Change
Cash From Investing Activities	-$46.00K	$25.15M	-$19.03K
YoY Change	141.72%	-132310.25%
FINANCING ACTIVITIES
Cash Dividend Paid		$4.412M
YoY Change
Common Stock Issuance & Retirement, Net		$155.0M
YoY Change		1490.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	88.00K	141.8M	8.290M
YoY Change	-98.94%	11776.38%
NET CHANGE
Cash From Operating Activities	-12.43M	-22.42M	4.041M
Cash From Investing Activities	-46.00K	25.15M	-19.03K
Cash From Financing Activities	88.00K	141.8M	8.290M
Net Change In Cash	-12.39M	144.5M	12.31M
YoY Change	-200.6%	-1356.05%	-353.34%
FREE CASH FLOW
Cash From Operating Activities	-$12.43M	-$22.42M	$4.041M
Capital Expenditures	-$46.00K	$46.00K	-$19.03K
Free Cash Flow	-$12.38M	-$22.47M	$4.060M
YoY Change	-404.97%	76.64%	-183.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y2M1D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M3D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M23D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y18D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y5M23D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0084
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0034
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8521
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8957
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0138
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0080
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8788
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9252
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite A250
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Pacific Palisades
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	90272
CY2021	dei	City Area Code CityAreaCode	424
CY2021	dei	Local Phone Number LocalPhoneNumber	473-8055
CY2021	dei	Security12b Title Security12bTitle	Common stock, $0.0001 par value per share
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2283000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	557000
CY2021Q4	us-gaap	Assets Assets	157910000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6439000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8445000
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	258000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	131000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15273000
CY2021Q4	us-gaap	Liabilities Liabilities	21504000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20894695
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20894695
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	279089000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142685000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	157910000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1120000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19670000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15008000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2121000
CY2021	dei	Auditor Firm AuditorFirmId	243
CY2021	dei	Auditor Name AuditorName	BDO USA, LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148989000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4455000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14149000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	81000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	151272000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	18685000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	119000
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3811000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2213000
CY2020Q4	us-gaap	Assets Assets	18825000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2392000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4099000
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	14314000
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	9029000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	99000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30058000
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1102000
CY2021Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	5757000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	474000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	97000
CY2020Q4	us-gaap	Liabilities Liabilities	31257000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2542358
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2542358
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	20161000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32595000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	136406000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-12432000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18825000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14580000
CY2021	aadi	Research And Development Related Party ResearchAndDevelopmentRelatedParty	200000
CY2020	aadi	Research And Development Related Party ResearchAndDevelopmentRelatedParty	2461000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18511000
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	74156000
CY2021	us-gaap	Operating Expenses OperatingExpenses	112337000
CY2020	us-gaap	Operating Expenses OperatingExpenses	17129000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-111217000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-2549000
CY2021	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-1585000
CY2020	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	153000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	196000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	13000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	41000
CY2021	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	600000
CY2020	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	734000
CY2021	us-gaap	Interest Expense InterestExpense	665000
CY2020	us-gaap	Interest Expense InterestExpense	815000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1129000
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-927000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-110088000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3476000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3478000
CY2021	aadi	Cumulative Dividends On Convertible Preferred Stock CumulativeDividendsOnConvertiblePreferredStock	647000
CY2020	aadi	Cumulative Dividends On Convertible Preferred Stock CumulativeDividendsOnConvertiblePreferredStock	987000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-110737000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4465000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-12.41
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.76
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8923369
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2542358
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-9093000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	139000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3478000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-1000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2106000
CY2021	aadi	Cumulative Dividends Paid On Series A Preferred Stock CumulativeDividendsPaidOnSeriesAPreferredStock	4412000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110090000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	136406000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110090000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3478000
CY2021	aadi	Impairment Of Acquired Contract Intangible Asset ImpairmentOfAcquiredContractIntangibleAsset	74156000
CY2021	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	1404000
CY2020	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	130000
CY2021	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-1585000
CY2020	aadi	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	153000
CY2021	us-gaap	Related Party Costs RelatedPartyCosts	578000
CY2020	us-gaap	Related Party Costs RelatedPartyCosts	734000
CY2021	aadi	Non Cash Interest Expense NonCashInterestExpense	665000
CY2020	aadi	Non Cash Interest Expense NonCashInterestExpense	815000
CY2021	aadi	Gain On Forgiveness Of Payroll Protection Plan Loan GainOnForgivenessOfPayrollProtectionPlanLoan	196000
CY2021	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	171000
CY2020	us-gaap	Provision For Loan And Lease Losses ProvisionForLoanAndLeaseLosses	167000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	105000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14149000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13864000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2166000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	22000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-481000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-37000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-129000
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-197000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8290000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1079000
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-8380000
CY2020	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	2461000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22423000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12701000
CY2021	aadi	Cash Acquired In Connection With Merger CashAcquiredInConnectionWithMerger	29700000
CY2021	aadi	Transaction Expenses Related To The Merger TransactionExpensesRelatedToTheMerger	4501000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25153000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	833000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	155000000
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9617000
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	4412000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142700000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-110100000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-3500000
CY2020	aadi	Proceeds From Issuance Of Convertible Promissory Notes ProceedsFromIssuanceOfConvertiblePromissoryNotes	1000000
CY2020	aadi	Proceeds From Payroll Protection Loan Program ProceedsFromPayrollProtectionLoanProgram	194000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	141804000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1194000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	144534000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11507000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4455000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15962000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	148989000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4455000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	22000
CY2021	aadi	Issuance Of Common Stock Upon Merger IssuanceOfCommonStockUponMerger	105888000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	610000
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	9130000
CY2021Q3	aadi	Anniversary Period Of Closing Of Merger Agreement AnniversaryPeriodOfClosingOfMergerAgreement	P20Y
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	155000000.0
CY2021	aadi	Proceeds From Issuance Of Common Stock Net ProceedsFromIssuanceOfCommonStockNet	145400000
CY2021	aadi	Cash Acquired In Connection With Merger CashAcquiredInConnectionWithMerger	29700000
CY2021	aadi	Cash Acquired In Connection With Merger Net CashAcquiredInConnectionWithMergerNet	27700000
CY2021	aadi	Cash Acquired In Connection With Merger After Compensation Expenses CashAcquiredInConnectionWithMergerAfterCompensationExpenses	2000000.0
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	149000000.0
CY2021Q3	us-gaap	Shares Outstanding SharesOutstanding	8100000
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2500000
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000.0
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	No fractional shares were issued in connection with the Reverse Stock Split.
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. In the opinion of management, all adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. The most significant estimates in the Company’s consolidated financial statements relate to fair value of the intangible asset, fair value of the convertible promissory notes, stock-based compensation expense and accrued research and development costs. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions. </p>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;color:#231F20;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration<span style="letter-spacing:0.05pt;"> </span>of Credit<span style="letter-spacing:0.05pt;"> </span>Risk</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-right:0.85%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents and certain investments in money market funds. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has not experienced any losses on deposits since inception.</p>
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0
CY2021Q4	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	3900000
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2021Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0
CY2021	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P14Y3M18D
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	698018
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	74200000
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	3900000
CY2021	aadi	Percentage Of Future Net Cash Proceeds Will Be Remitted To Contingent Value Rights Holders PercentageOfFutureNetCashProceedsWillBeRemittedToContingentValueRightsHolders	0.90
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P14Y3M18D
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	95000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3906000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	95000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3811000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	273000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	273000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	273000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	273000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	273000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	2446000
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3811000
CY2021Q4	aadi	Accrued Clinical Current AccruedClinicalCurrent	2507000
CY2020Q4	aadi	Accrued Clinical Current AccruedClinicalCurrent	2017000
CY2021Q4	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	2287000
CY2020Q4	aadi	Accrued Contract Manufacturing Current AccruedContractManufacturingCurrent	1301000
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1465000
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	597000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1948000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	11000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	238000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	173000
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8445000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4099000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	557000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	119000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	131000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	474000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	605000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	125000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	146000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	195000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	188000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	183000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	169000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	231000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	238000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	40000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	678000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	73000
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	605000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	131000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	474000
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0680
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20894695
CY2021	aadi	Right To Terminate License Agreement RightToTerminateLicenseAgreement	P120D
CY2021	aadi	Upfront Payment For License Agreement UpfrontPaymentForLicenseAgreement	14000000.0
CY2021Q1	aadi	Upfront Payment For License Agreement UpfrontPaymentForLicenseAgreement	14000000.0
CY2021	aadi	Amount Of Certain Development Regulatory And Sales Milestones Payments Eligible To Receive Under License Agreement AmountOfCertainDevelopmentRegulatoryAndSalesMilestonesPaymentsEligibleToReceiveUnderLicenseAgreement	257000000.0
CY2021Q4	aadi	Milestone Revenue Recognized MilestoneRevenueRecognized	1000000.0
CY2021	aadi	Milestone Payment Received MilestonePaymentReceived	1000000.0
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	8.63
CY2019Q4	aadi	Proceeds From Issuance Of Convertible Notes ProceedsFromIssuanceOfConvertibleNotes	8100000
CY2020Q1	aadi	Proceeds From Issuance Of Convertible Notes ProceedsFromIssuanceOfConvertibleNotes	1000000.0
CY2019Q4	aadi	Convertible Notes Interest Rate For Fourth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFourthMonthDateOfLoanAgreement	0.06
CY2020Q1	aadi	Convertible Notes Interest Rate For Fourth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFourthMonthDateOfLoanAgreement	0.06
CY2019Q4	aadi	Convertible Notes Interest Rate For Fifth And Sixth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFifthAndSixthMonthDateOfLoanAgreement	0.08
CY2020Q1	aadi	Convertible Notes Interest Rate For Fifth And Sixth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFifthAndSixthMonthDateOfLoanAgreement	0.08
CY2019Q4	aadi	Convertible Notes Interest Rate For Remaining Sixth Months Term Until Maturity At Twelve Months ConvertibleNotesInterestRateForRemainingSixthMonthsTermUntilMaturityAtTwelveMonths	0.10
CY2020Q1	aadi	Convertible Notes Interest Rate For Remaining Sixth Months Term Until Maturity At Twelve Months ConvertibleNotesInterestRateForRemainingSixthMonthsTermUntilMaturityAtTwelveMonths	0.10
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	25000000.0
CY2021Q4	aadi	Convertible Notes Interest Rate For Fourth Month Date Of Loan Agreement ConvertibleNotesInterestRateForFourthMonthDateOfLoanAgreement	0.80
CY2021	aadi	Convertible Notes Interest Rate In Five Or Six Months ConvertibleNotesInterestRateInFiveOrSixMonths	0.75
CY2021	aadi	Convertible Notes Interest Rate Later Than Six Months ConvertibleNotesInterestRateLaterThanSixMonths	0.70
CY2021	aadi	Outstanding Principal Percentage To Be Prepaid Within Four Months OutstandingPrincipalPercentageToBePrepaidWithinFourMonths	1.20
CY2021	aadi	Outstanding Principal Percentage To Be Prepaid Within Fifth And Sixth Months OutstandingPrincipalPercentageToBePrepaidWithinFifthAndSixthMonths	1.30
CY2021	aadi	Outstanding Principal Percentage To Be Prepaid After Sixth Month But Prior To Maturity OutstandingPrincipalPercentageToBePrepaidAfterSixthMonthButPriorToMaturity	1.40
CY2021	us-gaap	Troubled Debt Restructuring Debtor Current Period Description Of Changes In Terms TroubledDebtRestructuringDebtorCurrentPeriodDescriptionOfChangesInTerms	Private Aadi entered into an amendment to the October 2019 and January 2020 Convertible Notes, whereby the term was extended from one year to two years
CY2021Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	4.80
CY2021Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	698018
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2542358
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2558218
CY2021	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	390949
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.11
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	505000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1248520
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	26.05
CY2021	aadi	Share Based Compensation Arrangement By Share Based Payment Award Options Granted In Period Assumed Through Merger ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodAssumedThroughMerger	248258
CY2021	aadi	Share Based Compensation Arrangements By Share Based Payment Award Options Assumed Through Merger In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedThroughMergerInPeriodWeightedAverageExercisePrice	29.20
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	72316
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	65535
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	53.99
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1749876
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.71
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10007000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	444700
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	7585000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1749876
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	20.71
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10007000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2106000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	139000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	300000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.88
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.56
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	18.88
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.56
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	36666
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2019Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	40000
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.29
CY2021	aadi	Class Of Warrant Or Right Expiration Date ClassOfWarrantOrRightExpirationDate	2024-10-24
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.025
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.049
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.004
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.016
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.138
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.009
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.288
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.089
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.457
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34228000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7265000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3732000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2782000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1214000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	227000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39174000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10274000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38410000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10255000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	764000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	19000
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	764000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	19000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	764000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	28200000
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1600000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2404000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2210000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	24000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	294000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	194000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2674000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2404000
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2021	aadi	Net Operating Loss Cares Act Carryback Period NetOperatingLossCARESActCarrybackPeriod	P5Y
CY2021Q4	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	4800000
CY2020Q4	aadi	Accrued Clinical And Contract Manufacturing Expense AccruedClinicalAndContractManufacturingExpense	3300000

Files In Submission

Name	View Source	Status
0001564590-22-010721-index-headers.html	Edgar Link	pending
0001564590-22-010721-index.html	Edgar Link	pending
0001564590-22-010721.txt	Edgar Link	pending
0001564590-22-010721-xbrl.zip	Edgar Link	pending
aadi-10k_20211231.htm	Edgar Link	pending
aadi-10k_20211231_htm.xml	Edgar Link	completed
aadi-20211231.xsd	Edgar Link	pending
aadi-20211231_cal.xml	Edgar Link	unprocessable
aadi-20211231_def.xml	Edgar Link	unprocessable
aadi-20211231_lab.xml	Edgar Link	unprocessable
aadi-20211231_pre.xml	Edgar Link	unprocessable
aadi-ex105_377.htm	Edgar Link	pending
aadi-ex231_8.htm	Edgar Link	pending
aadi-ex311_10.htm	Edgar Link	pending
aadi-ex312_6.htm	Edgar Link	pending
aadi-ex321_7.htm	Edgar Link	pending
aadi-ex322_9.htm	Edgar Link	pending
aadi-ex41_619.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2jb0dfm0022000001.jpg	Edgar Link	pending
gi1eblcnkish000001.jpg	Edgar Link	pending
gi1eblcnkish000002.jpg	Edgar Link	pending
gi1eblcnkish000003.jpg	Edgar Link	pending
gi1eblcnkish000004.jpg	Edgar Link	pending
gi1eblcnkish000005.jpg	Edgar Link	pending
gi1eblcnkish000006.jpg	Edgar Link	pending
gi1eblcnkish000007.jpg	Edgar Link	pending
gi1eblcnkish000008.jpg	Edgar Link	pending
gi1eblcnkish000009.jpg	Edgar Link	pending
gi1eblcnkish000010.jpg	Edgar Link	pending
gi1eblcnkish000011.jpg	Edgar Link	pending
gi1eblcnkish000012.jpg	Edgar Link	pending
gi1eblcnkish000013.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AADI
Aadi Bioscience, Inc. Stock $aadi

2021 Q4 Form 10-K Financial Statement

#000156459022010721 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI Aadi Bioscience, Inc. Stock $aadi

2021 Q4 Form 10-K Financial Statement

#000156459022010721 Filed on March 17, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AADI
Aadi Bioscience, Inc. Stock $aadi